IRVINE, California – November 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2025, after market close on Wednesday, November 12, 2025.
| Title: | Mdxhealth Presents Third Quarter 2025 Financial Results and Corporate Update Conference Call and Webcast |
| Date: | November 12, 2025 |
| Time: | 4:30pm ET/ 22:30 CET |
| Conference Call Dial-in Details: | United States: 1-844-825-9789 Belgium: 0800 38 961 The Netherlands: 0800 94 94 506 United Kingdom: 0808 238 9064 |
| Conference ID: | 10203872 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1738892&tp_key=76bbbf3f0a |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.
About Mdxhealth
Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenomic, exosomal and other molecular signatures and assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Waltham, Massachusetts and Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
| For more information: This email address is being protected from spambots. You need JavaScript enabled to view it. LifeSci Advisors (IR & PR) John Fraunces Managing Director Tel: +1 917 355 2395 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$3.64 |
| Daily Change: | -0.33 -8.31 |
| Daily Volume: | 1,468,141 |
| Market Cap: | US$180.180M |
November 12, 2025 July 03, 2025 May 14, 2025 February 26, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
